Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2011

View Archived Issues

Serum KL-6 level is a biomarker of prognosis in diffuse alveolar hemorrhage syndrome

Genmab provides pipeline and technology update

Interim phase II data disclosed on nimotuzumab plus irinotecan in gastric cancer

StronBone Sr-substituted bioactive glass implants show promise in bone grafting

Phase I data reported on recombinant angiotensin-converting enzyme 2

Flex-590 confers chondroprotection in a model of osteoarthritis

AMG-369 reduces severity of experimental autoimmune encephalomyelitis

AstraZeneca responds to FDA complete response letter for Brilinta

CHMP issues positive opinion on Eisai's Halaven for metastatic breast cancer

Cytori Therapeutics' ADVANCE trial of ADRCs is cleared to begin in the Netherlands

New blockers of cyclic nucleotide-regulated HCN1 channel claimed

PGxHealth presents new adenosine A2A receptor agonists

Novartis receives Swiss and Austrian approval for Gilenya in relapsing-remitting MS

CHMP recommends European marketing authorization for Trobalt

R-Tech Ueno completes phase IIa RK-023 trial in androgenetic alopecia

CHMP recommends new indications of INOmax

New melanin-concentrating hormone MCH1 receptor antagonists claimed

FDA grants priority review for Optimer Pharma's fidaxomicin NDA

Enrollment complete in pivotal phase III trial of delayed-release cysteamine

Novel PI3K inhibitors described at Novartis

FDA approves Viibryd for major depressive disorder

Otuska submits application to extend indication for Abilify in Japan

FDA recommends approval of Bayer's gadobutrol injection

Eisai decides against submitting marketing applications for eritoran for severe sepsis

Eisai set to submit U.S. and E.U. marketing authorization applications for perampanel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...